NCT04872621Completed
Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation
Calquence 100 mg Capsules General Drug Use-Results Study; All Patient Investigation in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
Source: ClinicalTrials.gov · Last updated 2 Sept 2025
Brief summary (registry, in English)
To understand the incidence of ADRs of Calquence 100 mg capsules (acalabrutinib) used in patients with relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma) in a real-world post-marketing setting
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 104 (actual)
- First submitted
- 30 Apr 2021
- Start date
- 30 Jun 2021
- Primary completion date
- 4 Sept 2024
- Lead sponsor
- AstraZeneca
- NCT number
- NCT04872621
What you commit to
- Study type: Observational
- Participants enrolled: 104
- From 30 Jun 2021 to the primary completion date, 4 Sept 2024
- 40 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
- \-
Who the study is looking for
- Patients with relapsed or refractory chronic lymphocytic leukemia (small lymphocytic lymphoma) who are treated with the product -
Sex: All · Does not accept healthy volunteers
Sites (40)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.